Search

Lexicon Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

2.23 -0.89

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.23

Max

2.23

Belangrijke statistieken

By Trading Economics

Inkomsten

-32M

-33M

Verkoop

-20M

692K

EPS

-0.06

Winstmarge

-4,742.486

Werknemers

81

EBITDA

-30M

-29M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+167.86% upside

Dividenden

By Acuity

Volgende Winsten

5 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-34M

1B

Vorige openingsprijs

3.12

Vorige sluitingsprijs

2.23

Nieuwssentiment

By Acuity

50%

50%

131 / 339 Rangschikking in Healthcare

Lexicon Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 sep 2026, 00:00 UTC

Lexicon Pharmaceuticals Inc shares are higher in after-market trading, reflecting gains since Friday's close amid broader market dynamics and strong labor market data.

3 sep 2026, 19:26 UTC

Lexicon Pharmaceuticals Inc is higher today, with no specific news identified. Broader market declines in Treasury yields may be influencing trading.

24 aug 2026, 19:36 UTC

News

Lexicon Pharmaceuticals received a $10 million milestone payment from Novo Nordisk, bringing total payments to $75 million as shares rise during Monday's session.

21 aug 2026, 19:36 UTC

Lexicon Pharmaceuticals Inc shares are higher in Friday's session, continuing an upward trend since Thursday. The stock remains below its 20-day moving average.

20 aug 2026, 23:56 UTC

Lexicon Pharmaceuticals Inc shares are rising in after-market trading, showing positive momentum despite being below their 20-day moving average. No specific news was identified.

18 aug 2026, 19:31 UTC

Lexicon Pharmaceuticals Inc shares are higher today, driven by significant gains in the Biotechnology sub-sector. The stock is near its one-month high.

13 aug 2026, 19:56 UTC

Lexicon Pharmaceuticals is trading lower today amid no specific news. First-time claims for U.S. unemployment benefits rose, but investor sentiment remains stable.

12 aug 2026, 23:36 UTC

Lexicon Pharmaceuticals Inc's shares are higher in after-market trading, with no specific news identified. Broader market sentiment may be influenced by recent inflation data.

11 aug 2026, 23:26 UTC

Lexicon Pharmaceuticals Inc. shares are lower in after-market trading, with no specific news identified. Broader market sentiment remains cautious amid oil price developments.

10 aug 2026, 19:56 UTC

News

Lexicon Pharmaceuticals reported a second-quarter earnings loss of -$0.06 per share, missing expectations. Shares are lower amid a downgrade to “sell” from Wall Street Zen.

7 aug 2026, 22:01 UTC

Lexicon Pharmaceuticals Inc shares are lower in after-market hours, continuing a notable decline since Friday's close, with no specific news identified to explain the movement.

6 aug 2026, 23:26 UTC

Lexicon Pharmaceuticals shares are trading higher in after-market hours, following three consecutive sessions of declines. No specific news was identified for the price movement.

5 aug 2026, 19:36 UTC

News

Lexicon Pharmaceuticals Inc shares are lower as investors adjust positions ahead of Q2 earnings on August 5, with consensus EPS estimates at -$0.05.

4 aug 2026, 19:56 UTC

Lexicon Pharmaceuticals shares are higher today, reflecting strong momentum amid easing inflation concerns from declining crude oil prices. No specific news was identified.

31 jul 2026, 19:46 UTC

Lexicon Pharmaceuticals Inc shares are lower today, reflecting broader market trends amid rising yields and crude oil prices contributing to inflation concerns.

30 jul 2026, 23:11 UTC

Lexicon Pharmaceuticals Inc shares are lower in after-market hours. The decline follows broader market uncertainty after the Federal Reserve's interest rate decision.

29 jul 2026, 21:02 UTC

Lexicon Pharmaceuticals Inc shares are lower in after-market trading, reflecting broader market declines amid rising oil prices and geopolitical tensions in the Middle East.

27 jul 2026, 19:03 UTC

Lexicon Pharmaceuticals Inc is trading lower today, breaking a trend of higher daily closes. Broader market declines and falling oil prices may influence sentiment.

24 jul 2026, 20:07 UTC

Lexicon Pharmaceuticals Inc shares are lower today, reversing from earlier gains amid broader market volatility influenced by falling oil prices and inflation concerns.

22 jul 2026, 19:02 UTC

Lexicon Pharmaceuticals Inc shares are lower today, continuing a decline since Tuesday's close. The stock remains below its 20-day moving average.

21 jul 2026, 19:42 UTC

Lexicon Pharmaceuticals is higher as the market gains momentum, driven by strong performances from major companies and a resurgence in semiconductor stocks.

20 jul 2026, 19:06 UTC

Lexicon Pharmaceuticals Inc shares are lower today, following three days of gains. Broader market declines are linked to rising US Treasury yields and oil prices above $90.

Peer Vergelijking

Prijswijziging

Lexicon Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

167.86% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6 USD  167.86%

Hoogste 6 USD

Laagste 6 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Lexicon Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Sentiment

By Acuity

131 / 339 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
help-icon Live chat